Sandoz Adds To Anti-Infectives With Astellas Mycamine Deal
Global Micafungin Rights Valued At Up To $75m Upfront Plus Milestone Payments
Sandoz and Astellas have struck a deal that will see the Novartis subsidiary acquire global rights to the Mycamine micafungin antifungal brand, bolstering Sandoz’s anti-infectives portfolio and hospital offering.
